NASDAQ: NMRA - Neumora Therapeutics, Inc. Common Stock

半年間の収益性: +5.9%
セクタ: Healthcare

プロモーションスケジュール Neumora Therapeutics, Inc. Common Stock

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

さらに詳しく
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. The company was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Цена ао 11.85
ISIN US6409791000
EBITDA -0.0954
EV/EBITDA 1.99
Сайт https://neumoratx.com
Число акций ао 0.15883 млрд
P/BV 5.77
Валюта usd
IPO date 2023-09-14
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
1日あたりの価格変動: -28.14% (16.49)
週ごとの価格変動: -17.36% (14.34)
月ごとの料金変更: +0.1691% (11.83)
3ヶ月間の価格変動: +2.07% (11.61)
半年間の価格変動: +5.9% (11.19)
年間の価格変動: +19.58% (9.91)
年初からの価格変動: +2.33% (11.58)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 5.77 2
P/E 0 0
EV/EBITDA -12.47 0
合計: 2.25

効率

名前 意味 学年
ROA, % -47.55 0
ROE, % -50.3 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0279 10
合計: 9.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 0 0
収益性 Ebitda, % 96.57 9
収益性 EPS, % 127.36 10
合計: 7.8
さらに詳しく

機関 音量 共有, %
Softbank Group Corporation 7646916 4.81
FMR, LLC 6373129 4.01
MIC Capital Management UK LLP 4460700 2.81
ICONIQ Capital, LLC 3398628 2.14
Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust 3309123 2.08
Artal Group S.A. 2552702 1.61
EcoR1 Capital, LLC 2071450 1.3
Avidity Partners Management, LP 1990632 1.25
Johnson & Johnson 1849445 1.16
Citadel Advisors Llc 1843291 1.16

ETF 共有, % 年間の利益率, % 配当金, %
iShares U.S. Pharmaceuticals ETF 0.41562 17.60673599431 1.97922
iShares Morningstar Small-Cap ETF 0.01976 30.095066471445 1.60498
iShares Russell 2000 Growth ETF 0.08025 38.042556988 0.6026
iShares Russell 3000 ETF 0.00212 32.57283798366 1.43482
iShares Morningstar Small-Cap ETF 0.01976 391.25300933451 1.60498



スーパーバイザー 役職 支払い 生年
Mr. Paul L. Berns Co-Founder & Executive Chairman 1.65M 1967 (57 年)
Mr. Henry O. Gosebruch President, CEO & Director 3.33M 1973 (51 年)
Ms. Carol Suh Co-Founder & COO N/A 1990 (34 年)
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer N/A 1966 (58 年)
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer N/A 1974 (50 年)
Mr. Jason G. Duncan Chief Legal Officer 315k 1974 (50 年)
Mr. Michael Lee Milligan Principal Accounting Officer N/A
Mr. Robert Lenz M.D., Ph.D. Head of Research & Development 770.29k 1971 (53 年)
Dr. Joshua Pinto Ph.D. Chief Financial Officer 876.64k 1985 (39 年)
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor 1957 (67 年)

住所: United States, Watertown. MA, 490 Arsenal Way - Googleマップで開く, Yandexマップを開く
Webサイト: https://neumoratx.com